Aligos Therapeutics, Inc.
6 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Nov 2039
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Mar 19, 2027
- 3 fees due Apr 17 to 24, 2027 · next Apr 17
- 1 fee due May 21, 2027The maintenance fee for Tricyclic Compounds (US 11,820,773) comes due May 21, 2027. Unpaid by Nov 22, 2027, it lapses early.
- 2 fees due Jun 12 to 19, 2027 · next Jun 12
- 1 fee due Jul 2, 2027The maintenance fee for Bicyclic Pyridazinones and Methods of Use Thereof (US 11,858,913) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 1 fee due Sep 26, 2027The maintenance fee for Methods and compositions for targeting PD-L1 (US 11,939,581) comes due Sep 26, 2027. Unpaid by Mar 27, 2028, it lapses early.
- 2 fees due Oct 9 to 16, 2027 · next Oct 9
Recent changes
- 2 of the patents on this record were granted since Aug 20, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,166,976 | S-antigen transport inhibiting oligonucleotide polymers and methods In force · From the USPTO record | In force | From the USPTO record | |
| US 11,033,556 | Bicyclic sulfonamides In force · From the USPTO record | In force | From the USPTO record | |
| US 11,198,699 | Compounds targeting PRMT5 In force · From the USPTO record | In force | From the USPTO record | |
| US 11,091,467 | Modulators of Thr-Beta and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 12,180,192 | Modulators of Thr-Beta and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 12,599,582 | Pyrrole Compounds In force · High confidence | In force | High confidence | |
| US 11,136,321 | Tricyclic compounds In force · From the USPTO record | In force | From the USPTO record | |
| US 11,466,274 | Modified gapmer oligonucleotides and methods of use In force · From the USPTO record | In force | From the USPTO record | |
| US 11,464,783 | Heterocyclic compounds In force · From the USPTO record | In force | From the USPTO record | |
| US 11,613,750 | Methods of Reducing Virus Molecule Levels In force · High confidence | In force | High confidence |
Also on record, not counted in the 34: 6 patents in force now held by others. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
12 pending · 2 abandoned · 12 no status recorded